Chronic Adaptive versus Conventional Deep Brain Stimulation in Patients with Parkinson's Disease: A Randomized Crossover Trial with Exploratory Analysis of Baseline-Dependent Response Patterns

- Posted by system in English

Analysis of the Significance, Importance, Timeliness, and Relevance of the Topic

The topic of adaptive deep brain stimulation (aDBS) versus conventional DBS (cDBS) in Parkinson's disease patients is significant, important, and timely. Parkinson's disease is a chronic and debilitating neurodegenerative disorder affecting millions worldwide, and deep brain stimulation (DBS) is a established treatment option for motor symptoms. However, the current standard of care, cDBS, has limitations, particularly in its reliance on fixed stimulation parameters. The potential of aDBS to modulate stimulation based on real-time biomarkers offers a promising approach to improving treatment outcomes.

Breakdown of the Text and Relationships between Items

  1. Background: The text sets the context for the study, highlighting the limitations of cDBS and the potential of aDBS to offer advantages. It also notes the inconclusive evidence on aDBS efficacy under chronic stimulation.
  2. Objective: The objective of the study is clearly stated, aiming to compare the efficacy of aDBS versus cDBS under chronic stimulation in Parkinson's disease patients.
  3. Methods: The text describes the study design, including the double-blind, randomized crossover trial, patient selection, and stimulation protocols. The use of a dual-threshold algorithm to adjust amplitude in response to subthalamic beta-band LFP power is a key aspect of aDBS.
  4. Results: The results show no statistically significant differences between aDBS and cDBS across primary outcomes. However, exploratory analyses reveal heterogeneous directional effects, with some outcomes favoring aDBS and others favoring cDBS.
  5. Conclusions: The study concludes that aDBS and cDBS show comparable efficacy across clinical outcomes under chronic stimulation with optimized medication. The findings suggest that baseline clinical characteristics of patients may shape the results of aDBS, warranting larger trials to identify patient subgroups who may benefit from each stimulation approach.

Usefulness of the Text for Disease Management and Drug Discovery

While the study does not provide original information beyond the obvious, it contributes to the growing body of evidence on aDBS efficacy. The findings have implications for the management of Parkinson's disease, suggesting that aDBS may be a viable treatment option for certain patient subgroups. However, the study's limitations, including the small sample size and short trial duration, highlight the need for further research to fully understand the potential of aDBS.

Originality of Information

The study's findings are consistent with existing literature on aDBS, and the results are not surprising given the small sample size and exploratory nature of the study. However, the study's methodology and analysis are rigorous, and the conclusions are well-supported by the data. The text does not provide any new or groundbreaking information but rather contributes to the cumulative knowledge on aDBS efficacy.

Comparison with the State of the Art

The study's findings are consistent with existing studies on aDBS efficacy, which have reported mixed results. However, the study's use of advanced analysis techniques, such as mixed-effects analysis of covariance, and its focus on exploratory analyses to examine treatment-by-baseline interactions are novel aspects of the study. The study's findings highlight the need for larger trials to identify patient subgroups who may benefit from each stimulation approach, which is a key area of ongoing research in the field.

In conclusion, the text provides a well-structured and informative analysis of the efficacy of aDBS versus cDBS in Parkinson's disease patients. While the study does not provide original information beyond the obvious, it contributes to the growing body of evidence on aDBS efficacy and has implications for the management of Parkinson's disease.

Read the original article on medRxiv

Multiplexed temporal SWCNT biosensor combined with convolutional autoencoding identifies ALS-specific serum protein corona signatures

- Posted by system in English

Amyotrophic lateral sclerosis (ALS) lacks a validated blood-based diagnostic, and the field is increasingly moving from single-molecule markers toward integrative, multi-component signatures. Here we present a liquid-biopsy strategy that transduces disease-dependent serum-nanoparticle interactions into a learnable near-infrared spectral phenotype. A sensor array of twelve DNA-functionalized single-walled carbon nanotube (SWCNT) chiralities, functionalized with (GT)6 ssDNA coupled with a deep learning model was tested on serum from 20 ALS patients and 19 age- and sex-matched controls (n = 39, TargetALS). Our multiplexed sensor design (12 SWCNT chiralities) and data acquisition strategy based on excitation-emission matrices acquired at three timepoints (0, 6, 24 h) was conceived to maximize sensor carried information. Indeed, we show that the array generates partially independent temporal dynamics across chiralities governed primarily by tube diameter. To decode this multiplexed, time-resolved signal, we trained a dual-objective convolutional autoencoder that jointly optimizes reconstruction and classification, achieving 84.6% cross-validated accuracy (AUC = 0.87). Selected latent features were reproducible across an independent same-subject experimental batch and correlated with serum neurofilament light chain, linking the spectral phenotype to a clinically relevant neurodegeneration marker. Mass spectrometry supported a molecular basis for discrimination, revealing an ALS-biased protein corona enriched in adaptive-immune and inflammatory proteins. Together, these results establish proof of principle that time-resolved, multi-chirality SWCNT spectral sensing can compress complex serum composition into a reproducible near-infrared biomarker signature for ALS.

Read the original article on medRxiv

Elevated HbA1c is associated with advanced brain age in severe obesity

- Posted by system in English

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text explores the association between brain-predicted age and cardiometabolic risk factors in individuals with severe obesity. The topic is significant because it sheds light on the relationship between brain aging and obesity-related health conditions, which could have implications for disease management and drug discovery.

Significance

The study's focus on severe obesity is timely, given the rising prevalence of obesity worldwide and its impact on cognitive decline and mortality. The use of brain-predicted age as a machine learning biomarker is innovative and provides a new perspective on brain aging. The findings have the potential to improve our understanding of the mechanisms underlying brain-aging and obesity, which could inform the development of targeted interventions.

Importance

The study's results highlighting the association between high HbA1c levels and accelerated brain aging in individuals with severe obesity are important. This association suggests that managing blood glucose levels may be critical in preventing or slowing down brain aging in this population. The lack of association between BMI, hypertension, and hyperlipidemia and brain aging in severe obesity is also noteworthy, as it contradicts previous assumptions about the role of these factors in brain aging.

Timeliness

The study's focus on severe obesity is particularly relevant given the growing concern about obesity-related health conditions. The use of machine learning biomarkers, such as brain-predicted age, is a timely innovation in the field of neuroscience, as it holds promise for identifying individuals at risk of cognitive decline and dementia.

Relevance

The study's findings have relevance for disease management and drug discovery in several areas:

  1. Disease prevention: The association between high HbA1c levels and accelerated brain aging highlights the importance of managing blood glucose levels in preventing or slowing down brain aging.
  2. Targeted interventions: The study's results suggest that interventions aimed at reducing HbA1c levels may be effective in preventing or slowing down brain aging in individuals with severe obesity.
  3. Personalized medicine: The use of brain-predicted age as a machine learning biomarker could enable personalized medicine approaches, where treatments are tailored to an individual's specific risk profile.

Relationship between Items

The study's findings are related to each other in several ways:

  1. Brain-predicted age: The use of brain-predicted age as a machine learning biomarker is a key aspect of the study, which enables the identification of individuals at risk of cognitive decline and dementia.
  2. Cardiometabolic risk factors: The study examines the association between brain-predicted age and cardiometabolic risk factors, such as high HbA1c levels, BMI, hypertension, and hyperlipidemia, which are known to increase the risk of cognitive decline and dementia.
  3. Severe obesity: The study's focus on severe obesity is significant, given the rising prevalence of obesity worldwide and its impact on cognitive decline and mortality.
  4. Machine learning biomarkers: The use of machine learning biomarkers, such as brain-predicted age, is a timely innovation in the field of neuroscience, which holds promise for identifying individuals at risk of cognitive decline and dementia.

Usefulness for Disease Management or Drug Discovery

The study's findings are useful for disease management and drug discovery in several areas:

  1. Disease prevention: The association between high HbA1c levels and accelerated brain aging highlights the importance of managing blood glucose levels in preventing or slowing down brain aging.
  2. Targeted interventions: The study's results suggest that interventions aimed at reducing HbA1c levels may be effective in preventing or slowing down brain aging in individuals with severe obesity.
  3. Personalized medicine: The use of brain-predicted age as a machine learning biomarker could enable personalized medicine approaches, where treatments are tailored to an individual's specific risk profile.

Original Information beyond the Obvious

The study provides original information beyond the obvious in several areas:

  1. Association between high HbA1c levels and accelerated brain aging: The study's findings highlight the association between high HbA1c levels and accelerated brain aging, which has not been previously reported in the context of severe obesity.
  2. Limited agreement between ENIGMA and Pyment models: The study's results show limited agreement between ENIGMA and Pyment models in estimating brain-predicted age in individuals with severe obesity, which has implications for the development of machine learning biomarkers.
  3. Lack of association between BMI, hypertension, and hyperlipidemia and brain aging: The study's findings contradict previous assumptions about the role of BMI, hypertension, and hyperlipidemia in brain aging, highlighting the complexity of these relationships.

Read the original article on medRxiv


Please, help us continue to provide valuable information:

Useful Links

Quick Links

Get in Touch

Le Duzic, Hameau de la Goduçais, Le Minihic sur Rance, 35870, France

Contact the author